Literature DB >> 9127136

c-fos overexpression is associated with the pathoneogenesis of invasive cervical cancer.

T H Cheung1, J O Leung, T K Chung, S K Lam, K F To, Y F Wong.   

Abstract

The molecular genetics of human cervical cancer remains to be defined to a significant extent. The current study examined the prevalence and significance of proto-oncogene c-fos overexpression in cervical cancer. Immunohistochemical staining of c-fos oncoprotein was performed in 27 invasive cervical carcinomas and 30 cervical intraepithelial neoplasias (CINs) managed in our department. Eight normal cervical specimens were used as controls. In the patients with invasive cervical cancer, 8 were stage I, 12 were stage II, and 7 had stage III-IV disease. Three of the cancers were well differentiated, 18 were moderately differentiated and 6 were poorly differentiated. Twenty invasive cervical carcinomas (59%) and 3 CIN (10%) showed overexpression of c-fos. The difference is statistically significant (p < 0.001). No statistically significant relationship was found between c-fos overexpression and clinical stage, histological grade, or survival in invasive cervical cancer. In this population, c-fos overexpression appears to be common in invasive cervical cancer and correlated with the ability of the tumor to become invasive, but is not associated with the progression of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9127136     DOI: 10.1159/000291854

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  2 in total

1.  Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways.

Authors:  Carlos Pérez-Plasencia; Guelaguetza Vázquez-Ortiz; Ricardo López-Romero; Patricia Piña-Sanchez; José Moreno; Mauricio Salcedo
Journal:  Infect Agent Cancer       Date:  2007-09-06       Impact factor: 2.965

2.  Musashi-2, a novel oncoprotein promoting cervical cancer cell growth and invasion, is negatively regulated by p53-induced miR-143 and miR-107 activation.

Authors:  Peixin Dong; Ying Xiong; Sharon J B Hanley; Junming Yue; Hidemichi Watari
Journal:  J Exp Clin Cancer Res       Date:  2017-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.